Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis

• Published in: bioRxiv
• Main Authors: Bannoura, Sahar F, Aboukameel, Amro, Khan, Husain Yar, Uddin, Md Hafiz, Jang, Hyejeong, Beal, Eliza, Thangasamy, Amalraj, Kim, Seongho, Wagner, Kay Uwe, Mohammad, Ramzi, Al-Hallak, Mohammed Najeeb, Pasche, Boris C, Azmi, Asfar S
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 19.12.2023; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: 1-Phosphatidylinositol 3-kinase; Adenocarcinoma; AKT protein; Apoptosis; c-Myc protein; Cancer Biology; Cell cycle; Cell proliferation; CRISPR; Drug resistance; Gemcitabine; Localization; Malignancy; Metabolic pathways; Mitosis; Myc protein; Pancreas; Pancreatic cancer; Proteomes; Proteomics; RNA-mediated interference; Signal transduction; Therapeutic targets; Tumors; RCC1; PDAC; Pancreatic Cancer; Myc; Ran
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2023.12.18.572102

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. Here we for the first time evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC subsistence and drug resistance. RCC1 expression was found to be elevated in PDAC tissues in comparison with normal pancreatic tissues and was linked to poor prognosis. RCC1 silencing in a panel of PDAC cells by RNA interference and CRISPR-Cas9 resulted in reduced cellular proliferation in 2D and 3D cultures. RCC1 KD reduced migratory and clonogenic ability, enhanced apoptosis, and altered cell cycle distribution in human PDAC cells as well as cells isolated from the LSL-Kras LSL-Trp53 ;Pdx1-Cre (KPC) mouse tumors. Subcutaneous cell-derived xenografts show significantly attenuated growth of RCC1 KO tumors. Mechanistically, RCC1 knockdown resulted in disruption of subcellular Ran distribution indicating that stable nuclear Ran localization is critical for PDAC proliferation. Nuclear and cytosolic proteomic analysis revealed altered subcellular proteome in RCC1 KD KPC-tumor-derived cells. Altered cytoplasmic protein pathways include several metabolic pathways and PI3K-Akt signaling pathway. Pathways enriched in altered nuclear proteins include cell cycle, mitosis, and RNA regulation. RNA sequencing of RCC1 KO cells showed widespread transcriptional alterations. Upstream of RCC1, c-Myc activates the RCC1-Ran axis, and RCC1 KO enhances the sensitivity of PDAC cells to c-Myc inhibitors. Finally, RCC1 knockdown resulted in the sensitization of PDAC cells to Gemcitabine. Our results indicate that RCC1 is a potential therapeutic target in PDAC that warrants further clinical investigations.